论文部分内容阅读
目的替吉奥联合奈达铂同步三维适形放射治疗Ⅲ期非小细胞肺癌的临床疗效及安全性。方法选取2013年1月至2016年6月78例Ⅲ期非小细胞肺癌患者,根据治疗方案分组,每组39例。对照组给予吉西他滨联合奈达铂同步三维适形放射治疗,观察组给予替吉奥联合奈达铂同步三维适形放射治疗,均化疗4个疗程。统计两组临床疗效及不良反应。结果观察组治疗总有效率为74.36%,临床控制率为92.31%,与对照组(69.23%、89.74%)比较,差异未见统计学意义(P>0.05);两组消化道反应发生率差异未见统计学意义(P>0.05),观察组白细胞减少、血红蛋白减少、血小板减少发生率均低于对照组,差异有统计学意义(P<0.05)。结论给予Ⅲ期非小细胞肺癌替吉奥联合奈达铂同步三维适形放射治疗,临床效果显著,安全性高。
Objective To evaluate the clinical efficacy and safety of the combination of tegaserod and nedaplatin in the treatment of stage Ⅲ non-small cell lung cancer with concurrent three-dimensional conformal radiotherapy. Methods From January 2013 to June 2016, 78 patients with stage Ⅲ non-small cell lung cancer were selected and divided into three groups according to the treatment regimen: 39 cases in each group. The control group was given gemcitabine combined with nedaplatin synchronous three-dimensional conformal radiotherapy. The observation group was given tegaserod combined with nedaplatin synchronous three-dimensional conformal radiotherapy. All the patients were treated with 4 cycles of chemotherapy. The clinical efficacy and adverse reactions of the two groups were statistically analyzed. Results The total effective rate of observation group was 74.36%, the clinical control rate was 92.31%, which was not significantly different from that of control group (69.23%, 89.74%) (P> 0.05). The incidence of digestive tract reaction There was no statistical significance (P> 0.05). The leukopenia, hemoglobin and thrombocytopenia in the observation group were lower than those in the control group (P <0.05). Conclusions The three-dimensional conformal radiotherapy for the treatment of stage Ⅲ non-small cell lung cancer for the combination of gemcitabine and nedaplatin has significant clinical effect and high safety.